Managed Healthcare Executive3d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Monthly Prescribing Reference3d
FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis
The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
MedPage Today3d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The American Journal of Managed Care3d
FDA Approves Benralizumab for Eosinophilic Granulomatosis With Polyangiitis
The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
EuropaWire3d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
FiercePharma3d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
That changed on Tuesday however, as the FDA signed off on Fasenra for patients with eosinophilic granulomatosis with ...
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...